Icalziss

Calcium Chloride Dihydrate, the active ingredient in Icalziss, is a mineral salt presented as an extracorporeal use product for calcium supplementation in clinical settings. It is employed to correct low calcium levels during procedures such as dialysis or cardiac surgery. GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Icalziss provides calcium ions for extracorporeal therapies and is used in the following clinical situations: - Dialysis‑associated hypocalcemia: restores serum calcium to target ranges during renal replacement therapy. - Cardiopulmonary bypass: supplies calcium to support myocardial contractility and vascular tone. - Acute calcium depletion: corrects rapid drops in calcium during massive transfusion or citrate toxicity.

Icalziss may be associated with a range of adverse reactions, most of which are related to excess calcium exposure.

Common Side Effects: - Hypercalcemia: elevated serum calcium levels. - Hypotension: vasodilation due to calcium‑mediated vascular effects. - Nausea or vomiting. - Local irritation at infusion site. - Muscle weakness or cramps.

Serious or Rare Side Effects: - Cardiac arrhythmias: especially in patients with underlying heart disease. - Calcification of tissues: prolonged high calcium concentrations. - Metabolic alkalosis: secondary to chloride load. - Severe hypotension leading to shock. - Renal impairment exacerbation.

When using Icalziss, consider the following safety measures: - Serum calcium monitoring: check levels before, during, and after administration. - Cardiac monitoring: observe for arrhythmias, especially in patients with cardiac disease. - Renal function assessment: adjust use in patients with impaired kidney function. - Avoid in hypercalcemia: contraindicated when serum calcium is already elevated. - Compatibility check: ensure the solution is compatible with other intravenous fluids. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Icalziss can interact with other agents that affect calcium balance or cardiac conduction.

Major Interactions (Avoid): - Calcium channel blockers: may blunt therapeutic calcium effects and increase risk of hypotension. - Digoxin: excess calcium can potentiate digoxin toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase calcium excretion, requiring closer monitoring of serum levels. - Magnesium sulfate: concurrent high magnesium may exacerbate cardiac conduction disturbances. - Citrate‑containing blood products: may require dose adjustment to avoid calcium overload.